Intra-Cellular Therapies Inc (ITCI)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

430 EAST 29TH STREET NEW YORK, NY 10016

Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.

Data as of 2020-08-01
Market Cap1.317 Billion Shares Outstanding66.451 Million Avg 30-day Volume854.828 Thousand
P/E Ratio Dividend Yield EPS-2.78
Price/Sales1151.46 Price cash flow ratio Price free cash flow ratio-11.8
Book Value6.48 Price to Tangible Book3.19 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.039392
BETA1.79054 52-week High/Low43.56 / 6.75 Stddev0.388147
View SEC Filings from ITCI instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 0 (0.0%)
13F Filers holding this stock: 137 41 (2.69%)
Aggregate 13F shares on 03/31/2020: 46.547 Million 22.489 Million
Aggregate 13F shares on 12/31/2019: 38.028 Million 19.326 Million
Percent change: 22.40% 16.36%
Funds creating new positions: 33 16
Funds Adding to an existing position: 63 12
Funds closing out their position: 24 10
Funds reducing their position: 26 10
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 
Intra-Cellular Therapies Inc Chart by YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Check out our reporting and analysis

Funds Holding ITCI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ITCI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

28 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MARCUS JOEL S EXECUTIVE CHAIRMAN

  • Officer
  • Director
 331,931 2020-07-31 5

VAN NOSTRAND ROBERT L

  • Director
 7,567 2020-06-30 5

RIGGS RORY B

  • Director
 287,039 2020-06-30 6

ALAFI CHRISTOPHER D

  • Director
 5,692,246 2020-06-30 7

LERNER RICHARD A

  • Director
 105,827 2020-06-30 6

HINELINE LAWRENCE J. SVP OF FINANCE CFO

  • Officer
 0 2020-02-18 6

MATES SHARON CHAIRMAN, PRESIDENT & CEO

  • Officer
  • Director
 0 2020-02-18 5

HALSTEAD MICHAEL EVP AND GENERAL COUNSEL

  • Officer
 0 2020-02-18 5

SATLIN ANDREW EVP AND CHIEF MEDICAL OFFICER

  • Officer
 0 2020-02-18 2

NEUMANN MARK EVP, CHIEF COMMERCIAL OFFICER

  • Officer
 0 2020-02-18 3

VANOVER KIMBERLY E. SVP, EARLY STAGE CLINICAL DEV.

  • Officer
 27,068 2019-01-04 0

DAVIS ROBERT E SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
 43,989 2019-01-04 0

ALAFI MOSHE

  • 10% Owner
 3,953,270 2017-10-02 0

ALAFI CAPITAL CO LLC

  • 10% Owner
 3,953,270 2017-10-02 0

FIENBERG ALLEN A. VP OF BUSINESS DEVELOPMENT

  • Officer
 492,823 2015-08-19 0

WENNOGLE LAWRENCE P. VICE PRESIDENT, DRUG DISCOVERY

  • Officer
 126,500 2015-06-08 0

SOSLAND MORTON I.

  • 10% Owner
 3,638,389 2015-03-11 0

SANCHEZ JUAN F. VP, CORP. COMMUNICATIONS & IR

  • Officer
 0 2015-01-02 0

RAWLINS MICHAEL

  • Director
 0 2014-06-30 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MARCUS JOEL S - Director

2020-07-08 G 20,000 d 0 0.00 direct

ALAFI CHRISTOPHER D - Director

2020-06-30 A 613 $25.67 a 345,223 5,692,246.00 direct

LERNER RICHARD A - Director held by the lerner family trust uad 11/14/94

2020-06-30 A 584 $25.67 a 94,397 105,827.00 indirect

RIGGS RORY B - Director

2020-06-30 A 613 $25.67 a 60,369 287,039.00 direct

VAN NOSTRAND ROBERT L - Director

2020-06-30 A 275 $25.67 a 7,567 7,567.00 direct

RIGGS RORY B - Director

2020-06-25 M 14,005 a 59,756 286,426.00 direct

MARCUS JOEL S - Director

2020-06-25 M 14,005 a 28,379 1,258,675.00 direct

RIGGS RORY B - Director

2020-06-25 M 14,005 d 0 286,426.00 direct

MARCUS JOEL S - Director

2020-06-25 M 14,005 d 0 1,258,675.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments